JP2023510872A5 - - Google Patents
Info
- Publication number
- JP2023510872A5 JP2023510872A5 JP2022542899A JP2022542899A JP2023510872A5 JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5 JP 2022542899 A JP2022542899 A JP 2022542899A JP 2022542899 A JP2022542899 A JP 2022542899A JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5
- Authority
- JP
- Japan
- Prior art keywords
- molecules
- manipulated
- gene
- mhc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960607P | 2020-01-13 | 2020-01-13 | |
| US202062960617P | 2020-01-13 | 2020-01-13 | |
| US62/960,617 | 2020-01-13 | ||
| US62/960,607 | 2020-01-13 | ||
| PCT/US2021/013140 WO2021146222A1 (en) | 2020-01-13 | 2021-01-12 | Modification of blood type antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510872A JP2023510872A (ja) | 2023-03-15 |
| JP2023510872A5 true JP2023510872A5 (enExample) | 2024-01-22 |
| JP7853210B2 JP7853210B2 (ja) | 2026-04-28 |
Family
ID=74562041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542899A Active JP7853210B2 (ja) | 2020-01-13 | 2021-01-12 | 血液型抗原の修飾 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230272429A1 (enExample) |
| EP (1) | EP4090743A1 (enExample) |
| JP (1) | JP7853210B2 (enExample) |
| CN (1) | CN116234906A (enExample) |
| AU (1) | AU2021207810A1 (enExample) |
| CA (1) | CA3164591A1 (enExample) |
| WO (1) | WO2021146222A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CA3138597A1 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| IL308637A (en) * | 2021-05-19 | 2024-01-01 | Sana Biotechnology Inc | Primary hypoimmunogenic T cells are RHD negative |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| JP2024534771A (ja) | 2021-08-11 | 2024-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞 |
| US20250129346A1 (en) * | 2021-08-11 | 2025-04-24 | Sana Biotechnology, Inc. | Engineering cells for cell-based therapies, and associated compositions and methods |
| JP2024531234A (ja) | 2021-08-11 | 2024-08-29 | サナ バイオテクノロジー，インコーポレイテッド | 同種異系細胞療法のための遺伝子改変された初代細胞 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2025117331A1 (en) | 2023-12-01 | 2025-06-05 | Eli Lilly And Company | Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same |
| CN118291605A (zh) * | 2024-04-10 | 2024-07-05 | 深圳市血液中心(深圳市输血医学研究所) | 一种基于ngs的多系统红细胞血型基因分型方法和试剂盒 |
| CN118638907A (zh) * | 2024-06-26 | 2024-09-13 | 中国人民解放军联勤保障部队第九六〇医院 | 一种用于检测易漏检类孟买表型的snp标记 |
| CN119913243A (zh) * | 2025-04-01 | 2025-05-02 | 浙江省血液中心 | Abo血型变异体的snp位点、b亚型变异型血型鉴定试剂盒和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CN114634950A (zh) | 2012-12-12 | 2022-06-17 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP2016504026A (ja) | 2012-12-12 | 2016-02-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング |
| CA2988854A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| US20190330601A1 (en) * | 2016-05-13 | 2019-10-31 | University Of Copenhagen | A cell-based array platform |
| KR20190103373A (ko) | 2017-01-13 | 2019-09-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역조작된 만능 세포 |
| WO2018227286A1 (en) | 2017-06-12 | 2018-12-20 | Sinai Health System | Allograft tolerance without the need for systemic immune suppression |
| US11708559B2 (en) | 2017-10-27 | 2023-07-25 | The Children's Hospital Of Philadelphia | Engineered red blood cells having rare antigen phenotypes |
| US20210308183A1 (en) * | 2018-07-17 | 2021-10-07 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
| CN119372151A (zh) * | 2018-07-17 | 2025-01-28 | 加利福尼亚大学董事会 | 从免疫工程化多能细胞分化的细胞 |
| CA3138597A1 (en) * | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) * | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
-
2021
- 2021-01-12 CN CN202180022172.7A patent/CN116234906A/zh active Pending
- 2021-01-12 US US17/792,121 patent/US20230272429A1/en active Pending
- 2021-01-12 JP JP2022542899A patent/JP7853210B2/ja active Active
- 2021-01-12 WO PCT/US2021/013140 patent/WO2021146222A1/en not_active Ceased
- 2021-01-12 EP EP21704098.9A patent/EP4090743A1/en active Pending
- 2021-01-12 AU AU2021207810A patent/AU2021207810A1/en active Pending
- 2021-01-12 CA CA3164591A patent/CA3164591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lanza et al. | Engineering universal cells that evade immune detection | |
| Gornalusse et al. | HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells | |
| JP2022543112A5 (enExample) | ||
| Sedlik et al. | Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells | |
| JP2024144548A (ja) | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 | |
| Kohn et al. | New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing | |
| JP2023002716A (ja) | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 | |
| Patel et al. | T-cell therapies for HIV: preclinical successes and current clinical strategies | |
| US9228007B1 (en) | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells | |
| CN114072516A (zh) | 经修饰的腺病毒 | |
| Esrick et al. | Genetic therapies for sickle cell disease | |
| JP2018076329A (ja) | Ｃｄ４＋ｔ細胞応答を向上するための修飾されたエピトープ | |
| JP7523357B2 (ja) | ウイルスベクター産生 | |
| CA3164591A1 (en) | Modification of blood type antigens | |
| CN108474003A (zh) | 包含微小rna识别元件的cmv载体 | |
| Levesque et al. | CRISPR-based therapeutic genome editing for inherited blood disorders | |
| Sii-Felice et al. | Innovative Therapies for Hemoglobin Disorders: K. Sii-Felice et al. | |
| Sheppard et al. | Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication | |
| AU2020370254B2 (en) | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice | |
| Hotblack et al. | Dendritic cells cross-present immunogenic lentivector-encoded antigen from transduced cells to prime functional T cell immunity | |
| Porteus | Knock-in editing: it functionally corrects! | |
| JP7714667B2 (ja) | 改変ヒト人工多能性幹細胞の製造方法 | |
| Rans et al. | The evolution of gene therapy in X-linked severe combined immunodeficiency | |
| Kaneko et al. | Uphill Battle of CRISPR/Cas9: A Budding Technology in Need of Refinement | |
| 栗原健 | Suppression of HBV replication by the expression of nickase-and nuclease dead-Cas9 |